Leadership Transition at Carl Zeiss Meditec AG

Carl Zeiss Meditec AG has announced a forthcoming change in executive leadership. Dr. Markus Weber, the company’s President and CEO, has informed the Supervisory Board of his decision to leave the company of his own accord. The Supervisory Board acknowledged and deeply regretted Dr. Weber’s decision. A mutual agreement was reached that his tenure will officially conclude on 31 May 2025.

Maximilian Foerst Appointed as President and CEO Effective 1 June 2025

The Supervisory Board has appointed Maximilian Foerst as the next President and CEO of Carl Zeiss Meditec AG, effective 1 June 2025.

Since 2009, Foerst has served as Head of ZEISS Greater China, overseeing business operations in the company’s largest global market by revenue, generating approximately €2 billion annually. His leadership responsibilities span:

• Sales and service operations across all four ZEISS business segments

• Seven production sites and three innovation centers

• Over 7,000 employees at more than 30 locations

Prior to his role in China, Foerst led ZEISS Group operations in Korea and France. He also held leadership roles within the ZEISS Medical Technology segment as Director of Sales and Marketing and Head of Product Management for Lasers in the Ophthalmology business unit.

Recognition of Dr. Weber’s Contributions

Andreas Pecher, Chairman of the Supervisory Board of Carl Zeiss Meditec AG and President and CEO of Carl Zeiss AG, praised Dr. Weber’s strategic legacy:

“Under Markus Weber’s leadership, Carl Zeiss Meditec AG has laid a very important strategic foundation and, as a technology leader in ophthalmology and microsurgery, is very well positioned for the future. With the acquisition of Dutch Ophthalmic Research Center (D.O.R.C.), he successfully expanded the company’s service portfolio.”

Pecher expressed gratitude for Dr. Weber’s exceptional dedication and successful tenure, wishing him well in future endeavors.

Statement from Dr. Markus Weber

Reflecting on his 22-year tenure at ZEISS, Dr. Weber stated:

“I would like to thank the Supervisory Board, all the customers, partners, and employees for the excellent cooperation and for putting their trust in me. After 22 years at ZEISS and being in my early 50s, now is the right time to once again take on an entirely new challenge. I wish my successor, Maximilian Foerst, all the best and continued success.”

Maximilian Foerst on His New Role

“I am very much looking forward to this new position at Carl Zeiss Meditec AG. In challenging times, the company is very well positioned and aligned. The long-term potential of innovative medical technology is driven by megatrends such as demographic change, the growing importance of health, and digitalization. Now, we must leverage this potential with a keen eye on the diverse requirements of our global markets.”

Updated Executive Leadership Structure

Effective 1 June 2025, the Management Board of Carl Zeiss Meditec AG will consist of Maximilian Foerst as President and CEO, and Justus Wehmer as Chief Financial Officer.